Predictive biomarkers for pathological complete response in early-stage triple negative breast cancer following neoadjuvant chemotherapy

被引：0
|
作者：
Polho, Gabriel Berlingieri
Testa, Laura
Barroso-Sousa, Romualdo
Bonadio, Renata Colombo
机构：
[1] Univ Sao Paulo, Inst Canc Estado Sao Paulo ICESP, Sao Paulo, Brazil
[2] Inst Canc Estado Sao Paulo ICESP, Sao Paulo, Brazil
[3] Grp Dasa, Brasilia, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
598
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)
    Wein, Lironne
    Loi, Sherene
    BREAST, 2017, 34 : S27 - S30
  • [42] Neoadjuvant chemotherapy (NACT) use and response in US patients with early-stage triple-negative breast cancer in the National Cancer Database (NCDB)
    Kashyap, M.
    Downer, M.
    Debiasi, M.
    Russell, K.
    Craggs, C.
    Luhn, P.
    Pollom, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S320 - S321
  • [43] Predictive value of tumour infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancer
    Babbar, P. N.
    ANNALS OF ONCOLOGY, 2020, 31 : S1239 - S1239
  • [44] Circulating lymphocytes and pathologic complete response rate among patients with early stage triple negative breast cancer treated with neoadjuvant chemotherapy
    Talamantes, S. M.
    Costa, R. L.
    Rademaker, A.
    Santa-Maria, C. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [45] A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence
    Fournier, Marcia, V
    Goodwin, Edward C.
    Chen, Joan
    Obenauer, John C.
    Tannenbaum, Susan H.
    Brufsky, Adam M.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [46] A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence
    Marcia V. Fournier
    Edward C. Goodwin
    Joan Chen
    John C. Obenauer
    Susan H. Tannenbaum
    Adam M. Brufsky
    Scientific Reports, 9
  • [47] Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer
    Hao, Xiaopeng
    Gao, Xianqi
    Yin, Shanshan
    Jiang, Zefei
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [48] Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
    Esteva, Francisco J.
    Hortobagyi, Gabriel N.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (08) : 521 - 523
  • [49] Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response
    Kern, Peter
    Kalisch, Anne
    Kolberg, Hans-Christian
    Kimmig, Rainer
    Otterbach, Friederich
    von Minckwitz, Gunter
    Sikov, William M.
    Pott, Dirk
    Kurbacher, Christian
    CHEMOTHERAPY, 2013, 59 (05) : 387 - 394
  • [50] Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival
    Kern, Peter
    Kalisch, Anne
    von Minckwitz, Gunter
    Puetter, Carolin
    Kolberg, Hans-Christian
    Pott, Dirk
    Kurbacher, Christian
    Rezai, Mahdi
    Kimmig, Rainer
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (03) : 210 - 217
12345